计算核肿瘤学迈向精准放射性药物治疗:诊疗一体化数字孪生的伦理、监管与社会经济维度
该文由核医学与分子影像学会人工智能剂量学工作组提出计算核肿瘤学框架,旨在通过诊疗一体化数字孪生整合临床、生物标志物、影像与剂量学信息实现放射性药物治疗个体化。文章分析了实施该技术面临的社会、伦理与监管挑战,并提出了可能的解决方案。
要点
- 诊疗一体化数字孪生可整合多源信息模拟治疗场景并预测结局,推动超越一刀切的放射性药物治疗。
- 现行立法限制数据共享,而数字孪生恰恰受益于数据共享;匿名化常足够但伦理担忧可能阻碍无患者同意的共享。
- 治疗计划与验证中数据处理缺乏报销构成经济障碍;数字孪生所有权需清晰合同分配责任,复杂合同可能阻碍实施。
核心结论
- 基于机制的数字孪生框架可通过促进必要的信息交换来识别稳健的预后或预测性剂量学与生物标志物,从而引导学界走向个体化剂量学驱动的放射性药物治疗。
- 作者 caution 必须注意确保数字孪生技术以对社会负责的方式实施。
研究设计与样本
- 核医学与分子影像学会人工智能剂量学工作组从文献中梳理并讨论了实现诊疗一体化数字孪生的主要社会、伦理与监管挑战,并确定了可能的解决方案。
主要发现
- 该技术需要实施先进计算工具、协调统一的大规模实时数据收集以及建模协议,以实现跨机构互操作性。
- 当前立法限制数据共享,尽管数字孪生受益于此类数据;匿名化数据通常足够,但伦理担忧可能阻碍无患者同意的共享。
- 寻求伦理批准、采用联邦学习以及遵循指南等方法可解决该问题;准确且更新的数据输入对可靠的数字孪生输出至关重要。
- 治疗计划与验证中数据处理缺乏报销构成经济障碍;数字孪生所有权尤其在互联系统中需要清晰合同来分配责任,复杂合同可能阻碍实施。
- 需要稳健的安全措施防范数据泄露;无全球框架时跨境数据共享使风险管理复杂化。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Computational nuclear oncology for precision radiopharmaceutical therapy (RPT) is a new frontier for theranostic treatment personalization. A key strategy relies on the possibility to incorporate clinical, biomarker, image-based, and dosimetric information in theranostic digital twins (TDTs) of patients to move beyond a one-size-fits-all approach. The TDT framework enables treatment optimization by real-time monitoring of the real-world system, simulation of different treatment scenarios, and prediction of resulting treatment outcomes, as well as facilitating collaboration and knowledge sharing among health care professionals adopting a harmonized TDT. To this aim, the major social, ethical, and regulatory challenges related to TDT implementation and adoption have been analyzed. Methods: The artificial intelligence-dosimetry working group of the Society of Nuclear Medicine and Molecular Imaging is actively proposing, motivating, and developing the field of computational nuclear oncology, a unified set of scientific principles and mathematic models that describe the hierarchy of etiologic mechanisms involved in RPT dose response. The major social, ethical, and regulatory challenges to realize TDTs have been highlighted from the literature and discussed within the working group, and possible solutions have been identified. Results: This technology demands the implementation of advanced computational tools, harmonized and standardized collection of large real-time data, and modeling protocols to enable interoperability across institutions. However, current legislations limit data sharing despite TDTs' benefiting from such data. Although anonymizing data is often sufficient, ethical concerns may prevent sharing without patient consent. Approaches such as seeking ethical approval, adopting federated learning, and following guidelines can address this issue. Accurate and updated data input is crucial for reliable TDT output. Lack of reimbursement for data processing in treatment planning and verification poses an economic barrier. Ownership of TDTs, especially in interconnected systems, requires clear contracts to allocate liability. Complex contracts may hinder TDT implementation. Robust security measures are necessary to protect against data breaches. Cross-border data sharing complicates risk management without a global framework. Conclusion: A mechanism-based TDT framework can guide the community toward personalized dosimetry-driven RPT by facilitating the information exchange necessary to identify robust prognostic or predictive dosimetry and biomarkers. Although the future is bright, we caution that care must be taken to ensure that TDT technology is implemented in a socially responsible manner.
引用
- Strigari L, Schwarz J, Bradshaw T, et al. Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Ethical, Regulatory, and Socioeconomic Dimensions of Theranostic Digital Twins. J Nucl Med. 2025. PMID: 39848769. doi:10.2967/jnumed.124.268186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。